tradingkey.logo

Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer

ReutersMay 19, 2025 11:28 AM

- Zai Lab Ltd 9688.HK:

  • ZAI LAB RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ZL-1310, A DLL3-TARGETED ANTIBODY-DRUG CONJUGATE, FOR TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

  • ZAI LAB LTD - TO INITIATE PIVOTAL STUDY FOR ZL-1310 IN 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI